81 Citations (Scopus)

Abstract

Rheumatoid arthritis (RA) affects approximately 0.5-1% of the population and imposes substantial societal costs including an increased risk of work-related disability and accelerated mortality. It is increasingly clear that RA-related co-morbidities, including cardiovascular disease (CVD), infection, osteoporosis, lymphoproliferative malignancy, and peptic ulcer disease, serve as major determinants of disease-associated outcome. In this review, the impact of these select comorbidities on RA outcome is discussed. In addition, this review explores potential mechanisms underlying their association with RA, the possible iatrogenic role of agents used to treat the disease, and measures aimed at both prevention and treatment of disease-specific co-morbidity.

Original languageEnglish (US)
Pages (from-to)729-752
Number of pages24
JournalBest Practice and Research: Clinical Rheumatology
Volume17
Issue number5
DOIs
StatePublished - Jan 1 2003

Fingerprint

Rheumatoid Arthritis
Morbidity
Cardiovascular Infections
Peptic Ulcer
Osteoporosis
Comorbidity
Cardiovascular Diseases
Costs and Cost Analysis
Mortality
Population
Neoplasms

Keywords

  • Cardiovascular disease
  • Co-morbidity
  • Infection
  • Lymphoma
  • Osteoporosis
  • Peptic ulcer disease
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Co-morbidity in rheumatoid arthritis. / Mikuls, Ted R.

In: Best Practice and Research: Clinical Rheumatology, Vol. 17, No. 5, 01.01.2003, p. 729-752.

Research output: Contribution to journalReview article

@article{c76f975e818c4a0c930a70456618c803,
title = "Co-morbidity in rheumatoid arthritis",
abstract = "Rheumatoid arthritis (RA) affects approximately 0.5-1{\%} of the population and imposes substantial societal costs including an increased risk of work-related disability and accelerated mortality. It is increasingly clear that RA-related co-morbidities, including cardiovascular disease (CVD), infection, osteoporosis, lymphoproliferative malignancy, and peptic ulcer disease, serve as major determinants of disease-associated outcome. In this review, the impact of these select comorbidities on RA outcome is discussed. In addition, this review explores potential mechanisms underlying their association with RA, the possible iatrogenic role of agents used to treat the disease, and measures aimed at both prevention and treatment of disease-specific co-morbidity.",
keywords = "Cardiovascular disease, Co-morbidity, Infection, Lymphoma, Osteoporosis, Peptic ulcer disease, Rheumatoid arthritis",
author = "Mikuls, {Ted R}",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/S1521-6942(03)00041-X",
language = "English (US)",
volume = "17",
pages = "729--752",
journal = "Best Practice and Research in Clinical Rheumatology",
issn = "1521-6942",
publisher = "Bailliere Tindall Ltd",
number = "5",

}

TY - JOUR

T1 - Co-morbidity in rheumatoid arthritis

AU - Mikuls, Ted R

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Rheumatoid arthritis (RA) affects approximately 0.5-1% of the population and imposes substantial societal costs including an increased risk of work-related disability and accelerated mortality. It is increasingly clear that RA-related co-morbidities, including cardiovascular disease (CVD), infection, osteoporosis, lymphoproliferative malignancy, and peptic ulcer disease, serve as major determinants of disease-associated outcome. In this review, the impact of these select comorbidities on RA outcome is discussed. In addition, this review explores potential mechanisms underlying their association with RA, the possible iatrogenic role of agents used to treat the disease, and measures aimed at both prevention and treatment of disease-specific co-morbidity.

AB - Rheumatoid arthritis (RA) affects approximately 0.5-1% of the population and imposes substantial societal costs including an increased risk of work-related disability and accelerated mortality. It is increasingly clear that RA-related co-morbidities, including cardiovascular disease (CVD), infection, osteoporosis, lymphoproliferative malignancy, and peptic ulcer disease, serve as major determinants of disease-associated outcome. In this review, the impact of these select comorbidities on RA outcome is discussed. In addition, this review explores potential mechanisms underlying their association with RA, the possible iatrogenic role of agents used to treat the disease, and measures aimed at both prevention and treatment of disease-specific co-morbidity.

KW - Cardiovascular disease

KW - Co-morbidity

KW - Infection

KW - Lymphoma

KW - Osteoporosis

KW - Peptic ulcer disease

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0042427632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042427632&partnerID=8YFLogxK

U2 - 10.1016/S1521-6942(03)00041-X

DO - 10.1016/S1521-6942(03)00041-X

M3 - Review article

VL - 17

SP - 729

EP - 752

JO - Best Practice and Research in Clinical Rheumatology

JF - Best Practice and Research in Clinical Rheumatology

SN - 1521-6942

IS - 5

ER -